Aura Biosciences to Participate in Upcoming Investor Conferences Feb 25, 2026 07:00AM
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference Nov 24, 2025 04:05PM
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights Nov 13, 2025 07:00AM
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Sep 3, 2025 07:00AM
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights Aug 13, 2025 07:00AM
View Older Stories

May 15, 2025 06:01AM Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
May 1, 2025 04:01PM Aura Biosciences to Participate in Upcoming Investor Conferences
Apr 2, 2025 07:03AM Aura Biosciences (AURA) Announces Appointment of Teresa Bitetti to Board of Directors
Apr 2, 2025 07:00AM Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Mar 24, 2025 04:01PM Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Mar 24, 2025 07:00AM Aura Biosciences (AURA) Presents Positive Data from Phase 1 Trial of Bel-sar
Mar 24, 2025 07:00AM Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Mar 3, 2025 07:01AM Aura Biosciences (AURA) Announces Additional Data from Ongoing Phase 1 Trial
Mar 3, 2025 07:00AM Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urolo
Feb 25, 2025 07:00AM Aura Biosciences to Participate in Upcoming Investor Conferences
Nov 26, 2024 08:00AM Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Nov 12, 2024 04:05PM Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Oct 17, 2024 04:06PM Aura Biosciences (AURA): Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Ph
Oct 17, 2024 04:05PM Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Sep 12, 2024 06:30AM Aura Biosciences (AURA) Reports Positive Phase 2 End of Study Results Evaluating Bel-sar
Sep 12, 2024 06:30AM Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Feb 26, 2024 07:00AM Aura Biosciences to Participate in Upcoming Investor Conferences
Dec 7, 2023 08:00AM Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal
Nov 9, 2023 04:05PM Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Nov 8, 2023 07:00AM Aura Biosciences to Participate in Upcoming Investor Conferences
Nov 6, 2023 03:00PM Aura Biosciences (AURA) Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan
Nov 6, 2023 03:00PM Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
Oct 31, 2023 04:05PM Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melano
Oct 2, 2023 04:07PM Aura Biosciences (AURA) Strengthens and Expands Leadership Team with Key Appointments
Oct 2, 2023 04:05PM Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
Aug 9, 2023 07:00AM Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
May 24, 2023 04:05PM Aura Biosciences to Participate in Upcoming Investor Conferences
May 12, 2023 07:00AM Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
May 11, 2023 04:10PM Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Mar 15, 2023 04:10PM Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
Nov 10, 2022 07:00AM Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Nov 10, 2022 06:45AM Aura Biosciences (AURA) Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan
Nov 10, 2022 06:45AM Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
Nov 3, 2022 07:00AM Aura Biosciences to Participate in Upcoming Investor Conferences
Oct 3, 2022 07:03AM Aura Biosciences (AURA) Reports Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan
Oct 3, 2022 07:00AM Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma
Sep 28, 2022 07:00AM Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Sep 27, 2022 07:00AM Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanom
Sep 7, 2022 07:00AM Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
Sep 1, 2022 07:00AM Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
Aug 11, 2022 04:15PM Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Aug 2, 2022 07:00AM Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
Jun 30, 2022 07:01AM Aura Biosciences (AURA) Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Jun 30, 2022 07:00AM Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Jun 22, 2022 04:31PM Aura Biosciences (AURA) Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan versus Plaque Radiotherapy Supporting
Jun 22, 2022 04:30PM Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of
Jun 17, 2022 07:00AM Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
May 26, 2022 05:27PM Aura Biosciences (AURA) Reports Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors
May 26, 2022 05:26PM Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
May 25, 2022 07:00AM Aura Biosciences to Participate in Upcoming Investor Conferences
View Older Stories